

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



**Shanghai Henlius Biotech, Inc.**

**上海復宏漢霖生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2696)**

## **NOTICE OF EXTRAORDINARY GENERAL MEETING**

**NOTICE IS HEREBY GIVEN** that the extraordinary general meeting (the “**Meeting**”) of Shanghai Henlius Biotech, Inc. (the “**Company**”) will be held at Conference Room, 5th Floor, Innov Tower (Capitaland Building), Section A, 1801 Hongmei Road, Shanghai, PRC at 11:00 a.m. on Thursday, 28 July 2022 for the purposes of considering and, if thought fit, passing the following resolutions as ordinary resolutions:

### **ORDINARY RESOLUTIONS**

1. To consider and approve the resolutions in relation to the re-appointment and appointment of directors of the third session of the board of directors of the Company:
  - 1.1 the re-appointment of Mr. Wenjie Zhang as an executive director of the Company;
  - 1.2 the re-appointment of Mr. Qiyu Chen as a non-executive director of the Company;
  - 1.3 the re-appointment of Mr. Yifang Wu as a non-executive director of the Company;
  - 1.4 the re-appointment of Ms. Xiaohui Guan as a non-executive director of the Company;
  - 1.5 the appointment of Mr. Deyong Wen as a non-executive director of the Company;
  - 1.6 the re-appointment of Mr. Zihou Yan as a non-executive director of the Company;
  - 1.7 the re-appointment of Mr. Tak Young So as an independent non-executive director of the Company;

- 1.8 the re-appointment of Dr. Lik Yuen Chan as an independent non-executive director of the Company;
- 1.9 the re-appointment of Dr. Guoping Zhao as an independent non-executive director of the Company;
- 1.10 the re-appointment of Dr. Ruilin Song as an independent non-executive director of the Company;
- 2. To consider and approve the resolutions in relation to the re-appointment of shareholder representative supervisors of the third session of the board of supervisors of the Company:
  - 2.1 the re-appointment of Ms. Rongli Feng as a shareholder representative supervisor of the Company; and
  - 2.2 the re-appointment of Mr. Deli Kong as a shareholder representative supervisor of the Company.

On behalf of the Board  
**Shanghai Henlius Biotech, Inc.**  
**Wenjie Zhang**  
*Chairman*

*As at the date of this notice, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Dr. Aimin Hui and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.*

Hong Kong, 11 July 2022

*Notes:*

1. All resolutions at the Meeting will be taken by a poll pursuant to the articles of association of the Company and the Listing Rules. The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Listing Rules.
2. Any shareholder of the Company entitled to attend and vote at the Meeting is entitled to appoint a proxy (or more than one proxy if he/she holds more than one share) to attend and on a poll, vote on his/her behalf. A proxy needs not be a shareholder of the Company. If more than one proxy is so appointed, the form of proxy shall specify the number of shares in respect of which each such proxy is so appointed. In case of a poll every shareholder present in person or by proxy shall be entitled to one vote for each share held by him.
3. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be delivered to at the Company's Board secretary office (for holders of domestic shares or unlisted foreign shares), at 9th Floor, Innov Tower (Capitaland Building), Section A, 1801 Hongmei Road, Shanghai, PRC or the Company's H share registrar in Hong Kong (for holders of H shares), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 24 hours before the time appointed for the Meeting (i.e. not later than 11:00 a.m. on Wednesday, 27 July 2022) or the adjourned meeting (as the case may be). Completion and return of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
4. In order to determine the list of Shareholders who will be entitled to attend and vote at the Meeting, the registers of members of the Company will be closed from Monday, 25 July 2022 to Thursday, 28 July 2022 (both dates inclusive), during which period no transfer of shares of the Company will be effected. Shareholders whose names appear on the registers of members of the Company on Thursday, 28 July 2022 shall be entitled to attend and vote at the Meeting. In order to qualify for attending and voting at the Meeting, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration by 4:30 p.m. on Friday, 22 July 2022.
5. Shareholders who attend the Meeting in person or by proxy shall bear their own travelling and accommodation expenses.
6. References to time and dates in this notice are to Beijing time and dates.